| Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers S Mukhopadhyay, D Goswami, PP Adiseshaiah, W Burgan, M Yi, ... Cancer Research, 2020 | 172 | 2020 |
| The Metabolic Landscape of RAS-Driven Cancers from biology to therapy S Mukhopadhyay, MG Vander Heiden, F McCormick Nature Cancer 2 (March 2021), 271-283, 2021 | 154 | 2021 |
| The Enigma of Rapamycin Dosage S Mukhopadhyay, MA Frias, A Chatterjee, P Yellen, DA Foster Molecular Cancer Therapeutics, 2016 | 99 | 2016 |
| Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle M Saqcena, D Menon, D Patel, S Mukhopadhyay, V Chow, DA Foster PloS one 8 (8), e74157, 2013 | 94 | 2013 |
| Rapamycin-induced G1 cell cycle arrest employs both TGF- and Rb pathways A Chatterjee, S Mukhopadhyay, K Tung, D Patel, DA Foster Cancer Letters, 2015 | 70 | 2015 |
| Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs M Saqcena, S Mukhopadhyay*, C Hosny, A Alhamed, A Chatterjee, ... Oncogene, 2014 | 63 | 2014 |
| Reciprocal regulation of AMP-activated protein kinase and phospholipase D S Mukhopadhyay, M Saqcena, A Chatterjee, A Garcia, M Frias, DA Foster The Journal of Biological Chemistry, 2015 | 58 | 2015 |
| Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation S Mukhopadhyay, M Saqcena, DA Foster Oncoscience, 2015 | 46 | 2015 |
| 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells S Mukhopadhyay, A Chatterjee, D Kogan, D Patel, DA Foster Cell Cycle 14 (20), 3331-3339, 2015 | 43 | 2015 |
| Apoptotic effects of high-dose rapamycin occur in Sphase of the cell cycle M Saqcena, D Patel, D Menon, S Mukhopadhyay, F DA Cell Cycle, 2015 | 34 | 2015 |
| Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin D Salloum, S Mukhopadhyay, K Tung, A Polonetskaya, DA Foster Molecular cancer therapeutics 13 (3), 733-741, 2014 | 34 | 2014 |
| Phosphatidic acid drives mTORC1 lysosomal translocation in the absence of amino acids MA Frias, S Mukhopadhyay, E Lehman, A Walasek, M Utter, D Menon, ... Journal of Biological Chemistry 295 (1), 263-274, 2020 | 28 | 2020 |
| Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior D Goswami, D Chen, Y Yang, PR Gudla, J Columbus, K Worthy, M Rigby, ... Elife 9, e47654, 2020 | 24 | 2020 |
| Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer X Tong, AS Patel, E Kim, H Li, Y Chen, S Li, S Liu, J Dilly, KS Kapner, ... Cancer Cell, 2024 | 6 | 2024 |
| Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy S Mukhopadhyay, HY Huang, Z Lin, M Ranieri, S Li, S Sahu, Y Liu, YI Ban, ... Cancer Research, 2023 | 5 | 2023 |
| SHP2 Inhibitors for Treating Cancer S Mukhopadhyay, C Fedele, BG Neel https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2021 …, 2021 | | 2021 |
| Targeting glutaminolysis potentiates the efficacy of chemotherapy in RAS-driven pancreatic cancers S Mukhopadhyay, D Goswami, DV Nissley, F McCormick Cancer Research 80 (16_Supplement), 238-238, 2020 | | 2020 |
| Abstract A47: Targeting glutaminolysis potentiates the efficacy of chemotherapy in RAS-driven pancreatic cancers S Mukhopadhyay, P Adiseshaiah, D Goswami, DV Nissley, F McCormick Molecular Cancer Research 18 (5_Supplement), A47-A47, 2020 | | 2020 |
| Supplementary Data Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers S Mukhopadhyay, D Goswami, PP Adiseshaiah, W Burgan, M Yi, ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185043/bin/NIHMS1548762 …, 2020 | | 2020 |
| Exploiting Cancer Cell Signaling and Metabolism: Implications for Therapeutic Approach S Mukhopadhyay City University of New York, 2015 | | 2015 |
David FosterRosalyn Yalow Professor, Hunter College of the City University of New YorkVerified email at hunter.cuny.edu
